1. Tysabri (Natalizumab) Natalizumab (manufactured by Biogen Idec as Tysabri; previously named Antegren) is a humanized monoclonal [...]
Multiple sclerosis patients’ personal circumstances largely shape their views on therapy preferences
Opinions voiced by multiple sclerosis (MS) patients as to what they most want from, and like in, an MS treatment differ widely, although [...]
An extension of the phase II BOLD study found sustained reductions in gadolinium-enhancing T1 and new or enlarging T2 lesions over 2 years [...]
The Institute of Clinical and Economic Review (ICER) released the early draft of a paper intended to inform a future report evaluating [...]
The collective microenvironment of gut bacteria, called the gut microbiome, has come to receive attention in many research labs for its [...]
High blood pressure may be linked to greater overall disability in people with multiple sclerosis (MS), although the rate at which [...]
Individuals with genetically increased body mass indexes were at a greater risk for developing multiple sclerosis (MS), according to [...]
A team of scientists has created a new form of a vaccine used for the treatment of multiple sclerosis, one of the most severe [...]
Patients with multiple sclerosis (MS) have higher levels of a micro-RNA called miR-150 in their cerebrospinal fluid, a liquid surrounding [...]
Multiple sclerosis-related optic neuropathy can be reversed with allergy drug (antihistamine): study
Multiple sclerosis-related optic neuropathy can be reversed with allergy drugs (antihistamines), according to research. The preliminary [...]